Conclusion: Male,liver cirrhosis,HBcAb

posotive, elderly(age ≥65 years old) are independent risk factors for development of PLC in Hepatitis C patients.Patients with HCV infection and these risk factors should undergo more frequent screening than those without risk factors.The proporation of genotype 1 hepatitis C virus is the largest among all the patients. The incidence of genotype 1 HCV infection in the group of PLC is higher compared with the group of non-PLC,however,there MAPK inhibitor were no significant difference between the two groups.The relationship between genotype of HCV and PLC in Hepatitis C need futher large sample study. Key Word(s): 1. liver cancer; 2. hepatitis C virus; 3. risk factors; 4. logistic regression ; Presenting Author: SARAH JEANCODERA BELLIDO Additional Authors: IAN HOMERYEE CUA Corresponding

Author: SARAH JEANCODERA BELLIDO Affiliations: St. Luke’s Medical Center Objective: Patients with Hepatitis B coinfected with HIV have significantly more elevated serum HBV DNA levels with accelerated fibrogenesis and decompensation, giving them poorer prognosis. Studies on the efficacy of Tenofovir in Hepatitis B and HIV coinfection are mostly retrospective and observational, while existing randomized controlled studies are few with small sample size. This meta-analysis aims to study BMN 673 solubility dmso the efficacy of Tenofovir in the treatment of HIV-HBV coinfection by consolidating the results Bcl-w of the small trials. Methods: We selected randomized controlled studies comparing efficacy of Tenofovir versus control in the treatment of Hepatitis B-HIV coinfection, measuring the following

outcomes: mean change in the HBV DNA level, number of patients with undetectable HBV DNA level, normalization of ALT and HBeAg seroconversion at the end of 48 weeks. The quality of each study included was assessed by two independent and data was analyzed using Review Manager version 5. Results: Fifteen studies from the search were collected. Three studies, with a total of 79 patients, met the inclusion and exclusion criteria, as well as the quality scale assessment. The studies included were homogenous. The results show a trend favoring the use of Tenofovir in the treatment of Hepatitis B-HIV coinfection, with a mean difference of -1.74 log10 copies/ml (CI 1.30–2.18, p-value < 0.00001) from baseline in the HBV DNA level. HBV DNA levels were found to be undetectable in 42 (53%) patients using Tenofovir [RR 3.19 (CI 1.42 – 7.2, p-value = 0.005)]. Normal ALT levels were found in 15 patients after 48 weeks [RR 1.85 (CI 0.66 – 5.15, p-value = 0.52)], while no difference was observed in the HBeAg seroconversion. Conclusion: The use of Tenofovir as treatment of Hepatitis B infection among subjects coinfected with HIV showed a trend towards better efficacy compared to control in decreasing the mean HBV DNA and ALT levels. Key Word(s): 1. Tenofovir; 2. Hepatitis B – HIV ; 3.